More on BNTX

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+750.0% Growth)
- Ratings (6.7 Score)

Upcoming Events

- Earnings (11/3/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

BioNTech SE (NQ:BNTX)
Delayed: 88.12 -1.55 (1.73%)
Prev. Close $89.67  
Open$89.34 
52 Wk High$ 
52 Wk Low$ 
Day High$89.86 
Day Low$87.52 
P/E N/A  
EPS$ 
Volume838,703 

Friends, Peers and Foes (?): 0A3M, MRNA, PFE, NVAX, CVAC (more...)

Oct 25, 2026 03:30 AM BioNTech and Bristol Myers Squibb report Phase 2 data for pumitamig in NSCLC
Oct 25, 2026 03:30 AM BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
Oct 22, 2026 07:49 AM Form 6-K BioNTech SE For: Oct 22
Oct 22, 2026 06:45 AM BioNTech to adapt breast cancer trial to pair pumitamig with Gilead drug
Oct 22, 2026 06:45 AM BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer
Oct 20, 2026 06:45 AM BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026
Oct 19, 2026 07:26 AM Form 6-K BioNTech SE For: Oct 19
Oct 19, 2026 06:45 AM BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026
Oct 18, 2026 08:00 PM U.S. biotech SMids: Q3 earnings preview
Oct 14, 2026 06:35 AM BioNTech (BNTX) PT Lowered to $132 at Canaccord
View All Articles

Entities mentioned with BNTX

View All Entities